Revvity Q2 Earnings Call Highlights
Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.
How this was made
The 30-second read
Why it matters
For RVTY, the key tradable items are the raised full-year pro forma organic growth outlook, updated revenue/margin/EPS ranges, and the expectation for instruments to deliver positive mid-single-digit growth with reagents accelerating later in the year. Offsetting factors include a ~20% year-over-year Signals software decline and Life Sciences revenue down 2% reported and 3% organic.
Market read
Raised guidance and a stronger backlog narrative support RVTY’s forward growth profile, while software and Life Sciences declines highlight near-term execution and comparison risks.
What to watch
The guidance shift is partly driven by instrument shipment timing and contract renewal assumptions for Signals; traders should watch whether order velocity sustains into realized revenue.
Background
The piece summarizes Revvity’s Q2 earnings call, including segment results, leverage/financing details, and updated 2026 and Q3 guidance.
Ticker impact
Revvity raised 2026 pro forma organic growth to 4% to 5% and guided Q3 revenue and margins after Q2 segment performance and backlog strength.
Bias toward upward estimate revisions and supportive near-term trading, with volatility around Signals and Life Sciences order timing.
The article includes explicit updated full-year and Q3 targets, segment revenue trends, and a backlog/instrument demand narrative that can drive revisions, but it also flags a ~20% Signals software decline and Life Sciences revenue contraction.
Market effects
Signals AI and high-content screening instrument demand tied to AI drug discovery may reinforce sentiment for life-science tools and workflow software adoption.
Diagnostics growth outside China remained resilient despite latent TB testing pressure, suggesting less China concentration risk than peers.
AI-driven lab workflows and instrument backlog dynamics can influence broader expectations for biotech tools demand cycles.
Counterpoint
The raised instrument growth outlook may be offset by continued software weakness and difficult comparisons, so upside could fade if backlog converts slower than expected.
Key entities
- public_companyRevvity, Inc.
Life-sciences and diagnostics tools and software provider; subject of the earnings call highlights and guidance updates.
- partner_or_customerGenomics England
Referenced as a contributor to Reproductive Health comparisons and expected moderation in H2.
- technology_partnerAnthropic
Referenced via an announced connector for Signals AI to use customer data with Claude and Claude Science.
